Home
>
US Stocks
>
Rain Therapeutics Inc
Rain Therapeutics Inc
RAIN

Rain Therapeutics Inc (RAIN)

$14.847.38%

  • $

1D

1W

1M

1Y

3Y

5Y

Key Stats

Open$13.94
Today Low/High$13.94 / $15.2
52 Week Low/High$11.57 / $23.9
Market Cap$372.65M

Company Details

Rain Therapeutics Inc. is a clinical-stage precision oncology company developing therapies that target oncogenic drivers for which it is able to genetically select patients it believes will most likely benefit. This approach includes using a tumor-agnostic strategy to select patients based on their tumors’ underlying genetics rather than histology. Rain’s lead product candidate, RAIN-32 (milademetan, formerly known as DS-3032), is a small molecule, oral inhibitor of MDM2, which is oncogenic in numerous cancers. In addition to RAIN-32, Rain is also developing a preclinical program that is focused on inducing synthetic lethality in cancer cells by inhibiting RAD52.
OrganisationRain Therapeutics Inc

Discover more

Frequently Asked Questions

What is Rain Therapeutics Inc (RAIN) share price today?

Can Indians buy Rain Therapeutics Inc (RAIN) shares?

How can I buy Rain Therapeutics Inc (RAIN) shares from India?

Can Fractional shares of Rain Therapeutics Inc (RAIN) be purchased?

What are the documents required to start investing in Rain Therapeutics Inc (RAIN) stocks?

We are a SEBI registered investement advisor